1,277 results on '"Berger, Peter B."'
Search Results
2. Ad Hoc Percutaneous Coronary Intervention in Stable Patients With Multivessel or Unprotected Left Main Disease
3. The Association of Socioeconomic Factors With Percutaneous Coronary Intervention Outcomes
4. Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction Before and During COVID in New York
5. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention A Network Meta-Analysis
6. Delays in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock
7. 2017 Versus 2012 Appropriate Use Criteria for Percutaneous Coronary Interventions: Impact on Appropriateness Ratings
8. Temporal Trends in the Incidence, Prevalence, and Survival of Patients With Atrial Fibrillation From 2004 to 2016
9. Impact of COVID‐19 on percutaneous coronary intervention utilization and mortality in New York
10. The Impact of Excluding Shock Patients on Hospital and Physician Risk-Adjusted Mortality Rates for Percutaneous Coronary Interventions: The Implications for Public Reporting
11. Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation
12. Short-term Deaths After Percutaneous Coronary Intervention Discharge: Prevalence, Risk Factors, and Hospital Risk-Adjusted Mortality
13. Paroxysmal atrial fibrillation and the hazards of under-treatment
14. Appending Limited Clinical Data to an Administrative Database for Acute Myocardial Infarction Patients : The Impact on the Assessment of Hospital Quality
15. Treatment of Coronary Artery Disease and Acute Myocardial Infarction in Hospitals With and Without On-Site Coronary Artery Bypass Graft Surgery
16. Assessing Hospital Performance for Acute Myocardial Infarction : How Should Emergency Department Transfers Be Attributed
17. Cardiogenic Shock Complicating ST-Segment Elevation Acute Coronary Syndrome
18. Relation of Operator Volume and Access Site to Short-Term Mortality in Radial Versus Femoral Access for Primary Percutaneous Coronary Intervention
19. Utilization of Radial Artery Access for Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction in New York
20. Comparison of Intermediate-Term Outcomes of Coronary Artery Bypass Grafting Versus Drug-Eluting Stents for Patients ≥75 Years of Age
21. Plasma Ceramides: A Novel Predictor of Major Adverse Cardiovascular Events After Coronary Angiography
22. Impact of Regionalization of ST-Segment–Elevation Myocardial Infarction Care on Treatment Times and Outcomes for Emergency Medical Services–Transported Patients Presenting to Hospitals With Percutaneous Coronary Intervention: Mission: Lifeline Accelerator-2
23. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non‐small‐Cell Lung Cancer Receiving Erlotinib Treatment
24. Drug-Eluting Coronary Stents
25. Percutaneous Coronary Intervention With and Without Intravascular Ultrasound for Patients With Complex Lesions: Utilization, Mortality, and Target Vessel Revascularization
26. The New York State Risk Score for Predicting In-Hospital/30-Day Mortality Following Percutaneous Coronary Intervention
27. Readmission in the 30 Days After Percutaneous Coronary Intervention
28. Is 30-Day Mortality after Admission for Heart Failure an Appropriate Metric for Quality?
29. Impact of pre‐hospital electrocardiograms on time to treatment and one year outcome in a rural regional ST‐segment elevation myocardial infarction network
30. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial
31. Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segment–Elevation Myocardial Infarction Networks
32. Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: Results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry
33. Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
34. Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?
35. Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States
36. Frequency of Major Noncardiac Surgery and Subsequent Adverse Events in the Year After Drug-Eluting Stent Placement: Results From the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry
37. Outcomes After Implantation of the TAXUS Paclitaxel-Eluting Stent in Saphenous Vein Graft Lesions: Results From the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) Program
38. Predictors of Reperfusion Delay in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention from the HORIZONS-AMI Trial
39. Bleeding After Percutaneous Coronary Intervention With Bivalirudin or Unfractionated Heparin and One-Year Mortality
40. Finding the Proper Context for the MATRIX Trial
41. Does Preoperative Platelet Function Predict Bleeding in Patients Undergoing Off Pump Coronary Artery Bypass Surgery?
42. A Radial Resolution to a Warfarin Worry
43. Should Proton Pump Inhibitors Be Withheld From Patients Taking Clopidogrel?: The Issue That Has Been Giving Me Heartburn!
44. Validity of International Classification of Disease Codes to Identify Ischemic Stroke and Intracranial Hemorrhage Among Individuals With Associated Diagnosis of Atrial Fibrillation
45. Distal protection devices during percutaneous coronary and carotid interventions
46. Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial)
47. ST-elevation myocardial infarction patients can be enrolled in randomized trials before emergent coronary intervention without sacrificing door-to-balloon time
48. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry
49. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
50. Six-Month Follow-Up of Patients With In-Hospital Thrombocytopenia During Heparin-Based Anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] Registry)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.